US Investigator Meeting Held for Ph 3 HLX22-GC-301 in HER2+ Gastric Cancer
Jing Li, Vice President of Global Product Development at Henlius, said: “The U.S. investigator team plays a critical role in trial design interpretation, patient management, and execution quality for HLX22-GC-301. This investigator meeting provided an important platform for alignment and in-depth communication across sites, helping to further enhance consistency and standardization of trial implementation across regions. Henlius will continue to advance global clinical development to the highest standards, working closely with our international investigator partners to accelerate the global clinical validation and value realization of the differentiated innovative asset HLX22.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the